Biotech Values

[spartex]

<Please don’t be so binary—this is a matter of degree.>

I disagree, it is a matter of business intelligence based on experience investing in opportunities that have a level of risk, but more importantly a significant level of reward.

We're up ~45% from the DNDN lows this past year and recent news is giving WallStreet some concrete evidence to make decisions to accumulate DNDN shares.

Don't get too caught up in the degrees, or you'll miss the forest.